MX9603515A - Preparacion farmaceutica que contiene activadores de plasminogeno. - Google Patents

Preparacion farmaceutica que contiene activadores de plasminogeno.

Info

Publication number
MX9603515A
MX9603515A MX9603515A MX9603515A MX9603515A MX 9603515 A MX9603515 A MX 9603515A MX 9603515 A MX9603515 A MX 9603515A MX 9603515 A MX9603515 A MX 9603515A MX 9603515 A MX9603515 A MX 9603515A
Authority
MX
Mexico
Prior art keywords
sugar
tranexamic acid
lyophilisate
surfactant
injection
Prior art date
Application number
MX9603515A
Other languages
English (en)
Inventor
Ulrich Kohnert
Stephan Fischer
Hans-Jorg Markl
Heinrich Woog
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of MX9603515A publication Critical patent/MX9603515A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invencion se refiere a preparaciones farmacéuticas que contienen adyuvantes de plasminogeno, azucares y ácido tranexámico, en la forma de un liofilizado o una solucion de inyeccion o infusion. En particular, las preparaciones contienen un azucar, amortiguador de fosfatos, ácido tranexámico así como un agente tensioactivo y las soluciones líquidas tienen preferentemente un valor de pH de 5.5-6.5.
MX9603515A 1994-02-21 1995-02-18 Preparacion farmaceutica que contiene activadores de plasminogeno. MX9603515A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4405426A DE4405426A1 (de) 1994-02-21 1994-02-21 Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
PCT/EP1995/000596 WO1995022347A1 (de) 1994-02-21 1995-02-18 Pharmazeutisches präparat enthaltend plasminogenaktivatoren

Publications (1)

Publication Number Publication Date
MX9603515A true MX9603515A (es) 1997-03-29

Family

ID=6510724

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9603515A MX9603515A (es) 1994-02-21 1995-02-18 Preparacion farmaceutica que contiene activadores de plasminogeno.

Country Status (26)

Country Link
US (1) US5747030A (es)
EP (1) EP0746334B1 (es)
JP (1) JP3868997B2 (es)
KR (1) KR100356934B1 (es)
CN (1) CN1170591C (es)
AT (1) ATE205091T1 (es)
AU (1) AU691881B2 (es)
BR (1) BR9506840A (es)
CA (1) CA2183755C (es)
CZ (1) CZ286682B6 (es)
DE (2) DE4405426A1 (es)
DK (1) DK0746334T3 (es)
ES (1) ES2162913T3 (es)
FI (1) FI117925B (es)
HU (1) HU219769B (es)
MX (1) MX9603515A (es)
NO (1) NO317726B1 (es)
NZ (1) NZ281607A (es)
PL (1) PL181257B1 (es)
PT (1) PT746334E (es)
RU (1) RU2155067C2 (es)
SG (1) SG50567A1 (es)
SK (1) SK282827B6 (es)
TW (1) TW337997B (es)
WO (1) WO1995022347A1 (es)
ZA (1) ZA951371B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702680D0 (sv) * 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
US6653062B1 (en) * 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
US20050025825A1 (en) * 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
US20090214644A1 (en) * 2003-07-31 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations with reduced adverse effects
US7947739B2 (en) 2004-03-04 2011-05-24 Ferring B.V. Tranexamic acid formulations
US8022106B2 (en) * 2004-03-04 2011-09-20 Ferring B.V. Tranexamic acid formulations
US20050245614A1 (en) * 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US20050244495A1 (en) * 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US20090215898A1 (en) * 2004-03-04 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
KR101378194B1 (ko) 2005-12-20 2014-03-27 브리스톨-마이어스 스큅 컴퍼니 안정한 단백질 제제
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
US20100280117A1 (en) * 2009-04-30 2010-11-04 Xanodyne Pharmaceuticals, Inc. Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders
EP2968498A4 (en) 2013-03-15 2016-09-07 Biogen Ma Inc PREPARATIONS CONTAINING FACTOR IX POLYPEPTIDE
KR102385372B1 (ko) * 2014-03-24 2022-04-11 바이오버라티브 테라퓨틱스 인크. 동결건조된 ix 인자 제형
US11666532B2 (en) * 2018-01-19 2023-06-06 Hyloris Developments Sa Tranexamic acid oral solution
US10980757B2 (en) 2018-09-06 2021-04-20 RTU Pharma SA Ready-to-use tranexamic acid intravenous solution
AU2021325324A1 (en) * 2020-08-10 2023-02-23 Chiesi Farmaceutici S.P.A. Tissue plasminogen activator formulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3718889A1 (de) * 1987-06-05 1988-12-22 Behringwerke Ag Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin
DE3942144A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von k1k2p pro
DE3942141A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh K2p pro-stabilisierung
DE3942143A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa pro stabilisierung

Also Published As

Publication number Publication date
PT746334E (pt) 2002-02-28
CZ243196A3 (en) 1997-01-15
NZ281607A (en) 1997-04-24
KR970701059A (ko) 1997-03-17
TW337997B (en) 1998-08-11
CN1141592A (zh) 1997-01-29
PL315978A1 (en) 1996-12-23
CN1170591C (zh) 2004-10-13
HU219769B (hu) 2001-07-30
DE4405426A1 (de) 1995-08-24
NO963460D0 (no) 1996-08-20
JPH09511495A (ja) 1997-11-18
PL181257B1 (pl) 2001-06-29
HU9602284D0 (en) 1996-10-28
NO317726B1 (no) 2004-12-13
AU1758195A (en) 1995-09-04
SK107996A3 (en) 1997-04-09
DE59509580D1 (de) 2001-10-11
FI117925B (fi) 2007-04-30
EP0746334A1 (de) 1996-12-11
CZ286682B6 (en) 2000-06-14
FI963251A0 (fi) 1996-08-20
ES2162913T3 (es) 2002-01-16
EP0746334B1 (de) 2001-09-05
WO1995022347A1 (de) 1995-08-24
AU691881B2 (en) 1998-05-28
HUT74843A (en) 1997-02-28
SK282827B6 (sk) 2002-12-03
DK0746334T3 (da) 2001-12-27
SG50567A1 (en) 1998-07-20
CA2183755A1 (en) 1995-08-24
NO963460L (no) 1996-10-18
RU2155067C2 (ru) 2000-08-27
CA2183755C (en) 2004-02-17
FI963251A (fi) 1996-08-20
KR100356934B1 (ko) 2003-02-26
ZA951371B (en) 1996-08-20
JP3868997B2 (ja) 2007-01-17
US5747030A (en) 1998-05-05
BR9506840A (pt) 1997-10-14
ATE205091T1 (de) 2001-09-15

Similar Documents

Publication Publication Date Title
MX9603515A (es) Preparacion farmaceutica que contiene activadores de plasminogeno.
PL319833A1 (en) Compounds and composition for carrying active media
CS590188A2 (en) Method of erythropoietin's stabilized preparation production
CA2155762A1 (en) Protein Modification Method
EP0233013A3 (en) Modified enzyme
EP1329461B8 (en) Method of eliminating human serum albumin polymers
AR243602A1 (es) Procedimiento para obtener preparados liquidos acuosos suficientemente estables, de enzimas que tienen accion proteolitica.
HU912740D0 (en) Solubilisation of tissue plasminogene activator (t-pa)
WO1992002612A3 (en) Tissue plasminogen activator variants with decreased clearance
EP0277751A3 (en) Modified fibrinolytic enzyme
DE69423623T2 (de) Aminosäureergänzung
CA2165271A1 (en) Reduction of adipose tissue
CA2153787A1 (en) Solution containing igf-1
MX9707121A (es) Formulaciones liquidas de gch.
HU911112D0 (en) Liquid extraction containing active agents of natural origin, and process for the extraction of of the active agents, and cosmetical preparations with possible medicative effect containing such extraction

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: ACTAVIS GROUP PTC EHF.

MM Annulment or lapse due to non-payment of fees